Advanced Biotherapy and Innogenetics Combine Intellectual Property on Antibodies to Interferon-Gamma
Woodland Hills (California, USA) and Gent (Belgium) - Advanced Biotherapy Inc. and Innogenetics NV announced the signing of a cross-licensing agreement combining Innogenetics' patented humanized antibody to interferon-gamma (known as INNO 202) and Advanced Biotherapy's intellectual property in the field of various immune diseases involving interferon-gamma. By granting each other access to their respective intellectual property, the agreement provides a broader, joint position to attract interested third parties when negotiating mutually relevant development and commercial license agreements. The first clinical indication targeted in this arrangement is rheumatoid arthritis, but the agreement provides both companies with the option to target other widespread autoimmune conditions in the future. Proceeds resulting from the combined intellectual property will be shared between both companies.
"We are very pleased to collaborate with Innogenetics," stated Edmond Buccellato, CEO and Chairman of the Board of Advanced Biotherapy. "Combining patent portfolios and technical know-how will position us to deal effectively with third parties interested in treating autoimmune diseases using humanized antibodies to interferon-gamma."
Phillippe Archinard, CEO of Innogenetics added, "This collaboration also offers new licensing avenues for our humanized monoclonal antibody targeting interferon-gamma in therapeutic indications other than sepsis. Innogenetics will benefit from this partnership with a company that is strongly committed to developing interferon-gamma blocking agents, which fall outside Innogenetics' focus on therapeutic vaccines."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous